Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Topic: Emerging Relationships between the Gut Microbiome and Liver Cancer

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 15 Oct 2020

Guest Editor(s)

  • Mark Alan Feitelson, MD, PhD
    Professor, Molecular, Cellular, and Developmental Biology, Department of Biology, Temple University, USA.

    Website | E-mail

Special Issue Introduction

The gut microbiome is now considered an organ system which is central to maintaining metabolic and immunological homeostasis. It is involved in the production of compounds necessary for life, for the metabolism of many compounds that are ingested, and stimulates innate and adaptive immunity on the one hand, while tempering immune responses on the other. Alterations in the composition of bacteria (and other microbes) in the gut in a condition known as dysbiosis, are associated with an increasing and remarkable number of diseases characterized by chronic inflammation affecting multiple organ systems, including the liver. Hepatocellular carcinoma (HCC) is one of the many tumor types arising on a background of chronic inflammation. Importantly, HCC arises from many etiologies, including hepatitis B and C virus infections, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, alcoholic liver disease, as well as autoimmune hepatitis and from several genetic abnormalities. While it is not clear whether dysbiosis contributes to the cause or is the outcome of HCC, manipulation of the gut microbiome will likely help to re-establish the homeostasis. There is a long way to go, but there is no question that rebalancing the gut microbiome will be essential to recovering health as nature intended it.


1. Nahum Mendez-Sanchez & Ludovico Abenavoli Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico; Department of Health Sciences, University "Magna Graecia" Viale Europa, Catanzaro 88100, Italy.
2. Jian Wu, Chang Liu & Ning-Ping Zhang Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai, China.
3. Jin Zhou Program of Cardiovascular and Metabolic Disorders, Duke-NUS Medical School, Singapore.
4. Ilchom T. Murkamilov Department of Faculty Therapy, Kyrgyz State Medical Academy named after I.K. Akhunbaeva, Bishkek, Kyrgyzstan.
The list is arranged in no particular order and being updated.

Submission Deadline

15 Oct 2020

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 15 Oct 2020
Contacts: Ada Zhong, Assistant Editor,

Published Articles

Copyright © 2021 OAE Publishing Inc. All Rights Reserved.